Merus N.V.

Merus N.V. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl Read our Community Guidelines: https://merus.nl/community-guidelines/

Company Details

Employees
296
Address
Yalelaan 62, Utrecht,utrecht 3584 Cm,netherlands
Phone
31 30 253 8800
Email
en****@****erus.nl
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
merus.nl
HQ
Utrecht, Utrecht
Looking for a particular Merus N.V. employee's phone or email?

Merus N.v. Questions

News

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model - GlobeNewswire

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model GlobeNewswire

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewswire

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire

Genmab to buy Dutch biotech firm Merus for €6.8 billion - DutchNews.nl

Genmab to buy Dutch biotech firm Merus for €6.8 billion DutchNews.nl

Merus to Present at Upcoming Investor Conferences - FinancialContent

Merus to Present at Upcoming Investor Conferences FinancialContent

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewswire

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire

Merus’ Petosemtamab with Pembrolizumab Interim Data - GlobeNewswire

Merus’ Petosemtamab with Pembrolizumab Interim Data GlobeNewswire

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action - GlobeNewswire

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action GlobeNewswire

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting - GlobeNewswire

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting GlobeNewswire

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - GlobeNewswire

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs GlobeNewswire

Merus Announces FDA Approval of BIZENGRI® - GlobeNewswire

Merus Announces FDA Approval of BIZENGRI® GlobeNewswire

Merus and Partner Therapeutics Announce License Agreement - GlobeNewswire

Merus and Partner Therapeutics Announce License Agreement GlobeNewswire

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update - GlobeNewswire

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update GlobeNewswire

Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewswire

Merus N.V. Announces Proposed Public Offering of Common Shares GlobeNewswire

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update - GlobeNewswire

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update GlobeNewswire

Merus Awards Massive $15.7M Stock Options Package to Key New Hires in Oncology Push - Stock Titan

Merus Awards Massive $15.7M Stock Options Package to Key New Hires in Oncology Push Stock Titan

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - GlobeNewswire

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update GlobeNewswire

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety - GlobeNewswire

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety GlobeNewswire

Merus: Riding The Bispecific Wave In Oncology (NASDAQ:MRUS) - Seeking Alpha

Merus: Riding The Bispecific Wave In Oncology (NASDAQ:MRUS) Seeking Alpha

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewswire

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer GlobeNewswire

Phase 2 interim data: Merus' petosemtamab to be presented in plenary at AACR Oct 24; poster on cancer stem cells - Stock Titan

Phase 2 interim data: Merus' petosemtamab to be presented in plenary at AACR Oct 24; poster on cancer stem cells Stock Titan

Breakthrough: New Cancer Drug Petosemtamab Reveals 3 Ways to Fight Aggressive Tumors, Journal Study Shows - Stock Titan

Breakthrough: New Cancer Drug Petosemtamab Reveals 3 Ways to Fight Aggressive Tumors, Journal Study Shows Stock Titan

Merus (NASDAQ: MRUS) announces 100% responses in 1L left-sided mCRC with petosemtamab - Stock Titan

Merus (NASDAQ: MRUS) announces 100% responses in 1L left-sided mCRC with petosemtamab Stock Titan

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers - Business Wire

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers Business Wire

FDA Extends PDUFA Date for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer - OncLive

FDA Extends PDUFA Date for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer OncLive

Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 - Yahoo Finance

Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 Yahoo Finance

Vorläufige Ergebnisse von Merus zu Petosemtamab mit - GlobeNewswire

Vorläufige Ergebnisse von Merus zu Petosemtamab mit GlobeNewswire

Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics - Stock Titan

Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics Stock Titan

Merus NV (MRUS) Stock Price, Trades & News - GuruFocus

Merus NV (MRUS) Stock Price, Trades & News GuruFocus

Top Merus N.V. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant